Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

tigue, upper respiratory tract infection, nasopharyngitis, increased ALT, arthralgia, and headache. -- There were no deaths or treatment discontinuations due to adverse events. -- Nine percent (n=9/99) of patients experienced a serious adverse event. Serious adverse events included ALT elevation or hepatitis exacerbation (4), bilirubin elevation (1), inguinal hernia (1), sialoadenitis (1), thrombocytopenic purpura (1), groin pain (1), macular edema (1), urinary incontinence (1) and cholelithiasis (1). Two of these events, hepatitis exacerbation (1) and thrombocytopenia (1), were considered possibly related to treatment by the investigator. -- Five percent (n=5/99) of patients experienced an ALT flare on treatment (ALT > 2 times baseline and >10 times the upper level of normal) About BARACLUDE(R) (entecavir)

Discovered at Bristol-Myers Squibb, BARACLUDE(R) (entecavir) is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication with either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. BARACLUDE has been approved in more than 60 countries and regions around the world.

Important Information About BARACLUDE(R) (entecavir) 0.5mg/1mg Tablets

BARACLUDE(R) (entecavir) is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults where the virus is multiplying and damaging the liver. BARACLUDE does not cure HBV or stop the spread of HBV to others.

People should not take BARACLUDE if they are allergic to it or any of its ingredients. BARACLUDE has not been studied in children and is not recommended for anyone less than 16 years of age.

People taking BARACLUDE(R) (entecavir) should tell their healthcare provider right away if they feel very weak or tired, have unusual muscle pain, have trouble breathing, have stomach pain with nausea and vomiting, feel cold - especi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... 28, 2014 OmPrompt ... Millionen £ investiert hat, um die weltweite ... Pharma- und Logistikbranche zu erfüllen. Albion wird ... (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... sein beschleunigtes Wachstum mit Investitionen in seine ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... MINNEAPOLIS, Oct. 20 Uroplasty, Inc. (Nasdaq: ... results for the second quarter ended September 30, 2010, ...  The Company will host a conference call to discuss ... p.m. Central Time.  David Kaysen, President and Chief Executive ...
... 20 Genoptix, Inc. (Nasdaq: GXDX ), ... ranked number 41 on Technology Fast 500™, Deloitte,s ranking ... life sciences and clean technology companies in North America. ... growth during the five year period from 2005–2009. Genoptix ...
Cached Medicine Technology:Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010 2Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 3
(Date:7/28/2014)... 2014 Camp Soaring Eagle today ... property in Cornville, AZ. The nonprofit organization, founded ... the opportunity to attend medically supervised camps at ... organization offers a variety of programs to Arizona ... life threatening illnesses including: Illness Specific Camping Weekends, ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... are at risk of contracting meningitis because of specific ... to updated recommendations from the largest pediatrician group in ... the potentially deadly infection should continue for adolescents and ... In its first statement on meningococcal vaccines since 2011, ...
(Date:7/28/2014)... not divide unless there is enough oxygen present to ... cell types circumvent this rule. Researchers at The Johns ... the cells, warning signals, enabling cancers to continue to ... process, the researchers found that lysosomes the cell,s ... They also uncovered new evidence that certain drugs can ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Cell's recycling center implicated in division decisions 2
... is no exception. To all those who wish kick the ... mind-blowing news. Smokers // world over are swearing ... laser therapy, likened to a modern form of acupuncture has ... that of most other smoking cessation programmes. For the first ...
... the past have been recommended to take up a screening program ... cancer if any, at an early stage. // This would enable ... ,The need for the screening is further stressed in ... those of you who have still taken smoking very lightly, we ...
... University of California have now established a very strong ... renal disease. So if you are thinking over losing weight, ... to lose. // ,"There are more and ... much that kidney failure can be a consequence of obesity," ...
... Padua have found that the some complications // ... immediately after birth) could play a major role in ... anorexia nervosa and bulimia nervosa. ,Previous studies ... a complex interplay of genetic and environmental factors. Results ...
... founder president of the National Obesity Forum has resigned ... founding the national anti-obesity program at a time when ... obesity. Campbell’s resignation from the forum has taken many ... in the forum against him as they threatened him ...
... The American Society of Clinical Oncology has chosen 11 ... cancer for the year 2005. Prominent// among them is ... recurrence of HER-2-positive early-stage breast cancer. ... early-stage lung cancer is successful if chemotherapy is given ...
Cached Medicine News:Health News:Zap the butt (cigarette) with Laser Therapy 2Health News:CT Scan A Must For Smokers With Family History Of Lung Cancer 2Health News:Complications During Delivery Related To Eating Disorders 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: